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Titanium nanoparticles (TiO2)/graphene oxide
nanosheets (GO): an electrochemical sensing
platform for the sensitive and simultaneous
determination of benzocaine in the presence of
antipyrine†
Mona A. Mohamed, *a Shimaa A. Atty,a Hanan A. Merey,b Taghreed A. Fattah,a
Christopher W. Foster c and Craig E. Banks *c
An eﬀective electrochemical sensing platform for the simultaneous determination of benzocaine (BEN)
and antipyrine (ANT) based upon titanium dioxide nanoparticle (TiO2)/graphene oxide nanosheet (GO)
bulk modiﬁed carbon paste electrodes (TiO2–GO/CPE) is reported. The TiO2–GO/CPE electrochemical
sensing platform is found to exhibit linear ranges from 1.0 × 10−6 to 1.0 × 10−4 M and 1.2 × 10−8 to 8.0 ×
10−5 M for BEN and ANT, respectively. The TiO2–GO/CPE sensor is explored towards the analysis of BEN
and ANT in oral ﬂuid (saliva) and pharmaceutical products. The synergy between the graphene oxide
nanosheets and titanium dioxide nanoparticles results in a dramatic enhancement in the sensitivity of the
sensor through a combination of increased surface area and improved electron transfer kinetics com-
pared to other electrode alternatives. The fabricated TiO2–GO/CPE exhibits high sensitivity and good
stability towards the sensing of BEN and ANT and has the potential to be utilised as a clinical assay and QA
in pharmaceutical products.
1. Introduction
The Food and Drug Administration (FDA) issued a Public
Health Advisory warning about the risk of methemoglobi-
nemia (MHb) related to topical benzocaine used during medical
procedures1 and the FDA has received over 70 cases of serious
adverse events, with a number of deaths associated with MHb
after the use of topical benzocaine, bringing the total reported
cases to 319.2 Benzocaine (4-aminobenzoic ethyl ester) is a
local anaesthetic and as such is commonly found in medicines
for mild pain relief such as sore throat tablets and for reducing
the pain in mucous membranes and teguments.
Various pharmaceutical products contain benzocaine, such
as losenges, syrups, solutions, etc. used for the treatment of oral
or tongue ulcerations, gastric ulcers, as well as ointments and
suppositories used for treating hemorrhoidal disorders.3
Numerous experiments have shown that excessive doses of
anaesthetic sprays containing BEN can result in cyanosis and
life-threatening complications.4 Research findings have reported
that the administration of BEN containing sprays in endoscopy,
intubation, bronchoscopy, and similar invasive procedures may
cause MHb, with potentially serious consequences.4 In addition,
other research has revealed that a topical BEN 20% spray used
in endoscopies can be absorbed and cause MHb.5 There is
therefore a need to detect BEN in formulations for QA purposes
as well as in the analysis of raw materials, drugs and pharma-
ceutical preparations in addition to developing bioassays/bio-
monitoring. Several quantitative analytical studies for quantify-
ing BEN have been reported, involving high-performance liquid
chromatography (HPLC),6–8 liquid chromatography-mass spec-
trometry (LC-MS),9,10 amperometric detection using a modified
carbon-paste electrode8,11 and chemiluminescence.12,13
Antipyrine (ANT) and BEN are co-formulated in ear
drops for pain relief and reduction of inflammation in the
ear in otitis externa and acute otitis media.14 Antipyrine
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(1,5-dimethyl-2-phenyl-4-pyrazolin-3-one) is a non-steroidal
anti-inflammatory drug (NSAID) that can relieve mild to
moderate pain. ANT is an oﬃcial drug as reported in the
United States Pharmacopeia (USP)15 and British Pharmacopoeia
(BP).16 Numerous analytical methods have been reported for the
determination of ANT either alone or co-formulated with other
drugs, such techniques can include spectrophotometric,17–20
chromatographic,21,22 thin-layer chromatography (TLC),23,24 gas
chromatography (GC),25,26 capillary zone electrophoresis27 and
non-aqueous titration28 methods. Due to the harmful side
eﬀects of BEN towards humans, there is a need for selective and
fast highly eﬃcient analytical protocols for the determination of
trace BEN and its co-formulated drug antipyrine (ANT) in
human fluids and pharmaceutical preparations.
Graphene oxide (GO) is being widely combined into an ever
diversifying range of applications across several fields in the
search for greatly improved device performance.29 One area
that receives significant interest is electrochemistry where GO
has been reported to be beneficial for various applications
ranging from sensing through to energy storage/generation
and carbon-based molecular electronics as well as water
splitting.30–33 Additionally, GO can work as a building block
for the construction of three dimensional (3D) graphene with
various structures that can combine with other functional
materials to yield new 3D-based hierarchical materials.30
Graphene oxide (GO) has a high adsorption capacity, large
surface area and good biocompatibility. In particular, GO con-
tains a large number of hydrophilic functional groups, such as
–OH, –COOH and epoxides on the basal plane and the sheet
edge,34–36 resulting in good hydrophilicity that makes it easily
disperse in solvents with long-term stability. Due to these
advantages, GO-based electrochemical sensors have been
developed for the sensitive determination of various biological
molecules.35 The existence of oxygen functionalities at the
surface of GO is very interesting as they provide reactive sites
for chemical modification using well-known carbon surface
chemistry.37 One possible way to utilise the outstanding pro-
perties of GO in applications would be to integrate GO sheets
in a composite material which is then applied as the basis for
an electrochemical sensor.
In this paper, we have utilised the reported benefits of GO,
to design and develop a GO bulk modified carbon-paste
electrode. To provide further enhancements, we have addition-
ally incorporated nanomaterials, in this case, titanium dioxide
(TiO2) nanoparticles, due to their reported physicochemical pro-
perties such as good biocompatibility, strong adsorptive ability,
high surface area, thermal stability, non-toxicity and electrical/
electrochemical properties.38 To the best of our knowledge, and
at the time of writing this, there are no studies reported to date
that utilise TiO2–GO for the electrochemical determination of
BEN and ANT. We consequently report the first ever example of
using TiO2–GO/CPE electrodes for the bio-monitoring of BEN
and ANT in oral fluid (saliva) and pharmaceutical products. The
TiO2–GO/CPE based electrochemical sensing platform provides
a simple, selective and reliable sensor for the simultaneous
determination of BEN and ANT.
2. Experimental
2.1. Instrumentation
A Bio-logic SP 150 electrochemical workstation was used for all
electrochemical measurements. A one compartment cell with
a three electrode set-up was connected to the electrochemical
workstation through a C3-stand from BAS (USA). A platinum
wire from BAS (USA) was employed as the auxiliary electrode.
All the cell potentials were measured with respect to an
Ag/AgCl (3.0 M NaCl) reference electrode from BAS (USA).
A Cyberscan 500 digital (EUTECH Instruments, USA) pH-meter
with a glass combination electrode served to carry out pH
measurements. All the electrochemical experiments were per-
formed at an ambient temperature of 25 °C. Impedance
spectra were recorded over a frequency range from 100 mHz to
100 kHz. Scanning electron microscopy (SEM) measurements
were carried out using a JSM-6700F scanning electron micro-
scope (Japan Electro Company). FT-IR spectra were recorded
on an IR-Aﬃnity-1 Fourier transform infrared spectrophoto-
meter (Shimadzu, Japan). The crystalline phases were detected
and identified using an X-ray diﬀractometer (XRD) on an
X’Pert PRO MRD with a copper source at a scan rate (2θ) of
1° s−1. Sigma Plot 10.0 was used for all statistical data.
2.2. Chemicals and reagents
BEN was kindly supplied by Sabaa International Company
(Egypt), purity: 99.98%. ANT was kindly supplied by Pharma
Swede Egypt, purity: 99.88%. Graphite powder was obtained
from Aldrich. The dosage form, Otosept ear drops (labelled to
contain 300 mg of antipyrine and 100 mg of benzocaine) are
manufactured by Amriya for pharmaceutical industries, Egypt.
Zora-C lozenges (labelled to contain benzalkonium chloride
0.001 mL, benzocaine 1.0 mg and vitamin C 50.0 mg) is manu-
factured by CID Company. Titanium dioxide nanoparticles
were obtained from Nano-Lab (Waltham, MA, USA). Paraﬃn
oil from Merck was used as the pasting liquid for the prepa-
ration of the paste electrodes. Britton–Robinson buﬀer (BRB)
was prepared by mixing diﬀerent volumes of 0.04 M in H3PO4,
0.04 M acetic acid and 0.04 M boric acid with an appropriate
amount of 0.2 M NaOH to obtain the desired pH 2.0–10.0. All
solutions were prepared from analytical grade chemicals and
sterilized Milli-Q deionized water was used.
2.3. Preparation of the GO–TiO2–CPE
Carbon paste unmodified electrodes (CPEs) were prepared by
mixing graphite powder (0.5 g) with paraﬃn oil (0.3 mL) in a
pestle and mortar. The carbon paste was packed into the hole
of an electrode body and smoothed on filter paper until a
shiny appearance was achieved. Graphene oxide (GO) was pre-
pared by using Hummers’ method.39 TiO2 was dispersed with
GO in water by adding 100.0 mg TiO2 and 100.0 mg GO in a
25 mL volumetric flask (1 : 1, wt% : wt%) and sonicated for
45 min to produce a homogeneous dispersion. The TiO2–GO
nanocomposite was then left to dry at 80 °C in an oven for
4 hours. Next, 30.0 mg of the TiO2–GO nanocomposite (1 : 1)
was mixed with 970.0 mg graphite. The paste was extensively
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mixed with an appropriate amount of paraﬃn oil (0.35 mL) for
40 min until a uniform and homogeneous wetted paste was
obtained. This paste was packed into the hole of the electrode
body and smoothed on filter paper until a shiny appearance
occured. A new surface was obtained by pushing excess of the
paste out of the syringe and polished with weighing paper.
Other modified CPEs were prepared for comparative studies.
Accordingly, TiO2/CPE and GO/CPE were made using 15.0 mg
of TiO2 and GO separately with 985.0 mg of graphite. The
same amount of paraﬃn oil was used for the preparation of
partially bulk modified CPEs.
Prior to any voltammetric measurements, the modified
TiO2–GO/CPE electrode was cycled between 0.0 and −1400 mV
at a scan rate of 100 mV s−1 in a pH 2 BRB several times until
a reproducible response was achieved. Following this, the
modified TiO2–GO/CPE electrode was transferred into another
cell containing pH 2 BRB.
2.4. Analysis of real samples
Otosept ear drops. A volume of ear drops equivalent to 1.0 ×
10−3 M BEN and ANT was transferred into a volumetric flask
(10 mL) and made up to the mark with double distilled water.
An appropriate dilution was made using double distilled
water to obtain solutions of the final concentrations of BEN
and ANT.
Five tablets were weighed and transferred to a clean, dry
mortar. An accurately weighed amount equivalent to two
tablets was dissolved in 10 mL of distilled water to give a solu-
tion containing 1.2 × 10−3 M BEN; this was then diluted to give
1.0 × 10−3 M BEN, which was then filtered through a Nylon
membrane filter.
Oral fluid (saliva). Collection of saliva samples was achieved
using a salivette from a healthy volunteer who received
repeated doses of Zora-C lozenges (once daily) within a
pharmacokinetic study.40 The saliva samples were centrifuged
for 5 min at 4000 rpm, then diluted to 5.0 mL with pH 2 BRB
and were analysed using the standard addition method. The
solution was transferred into the voltammetric cell to be ana-
lysed without any further pretreatment. All experiments were
performed in compliance with the relevant laws and insti-
tutional guidelines, and the institutional ethics committees
have approved these experiments.
3. Results and discussion
3.1 Electrochemical characterisation of the TiO2–GO/CPE
The GO–TiO2 used in the fabrication of the TiO2–GO/CPE
electrochemical sensors is fully characterised and presented
in the ESI (Fig. S1 and S2†) confirming the presence of
nanometer-sized TiO2 supported on graphene oxide (GO)
nanosheets where the GO serves to electrically wire and
support the TiO2 electroactive centres. To demonstrate the
benefits of using the TiO2–GO/CPE as the basis for a sensor,
the electrochemical response was explored using not only the
TiO2–GO/CPE, but also a bare CPE, TiO2/CPE and GO/CPE.
The cyclic voltammetric responses are shown in Fig. 1A
where in all cases, two voltammetric peaks are observed
corresponding to the electrochemical oxidation of BEN and
ANT. It is evident that the largest voltammetric response is
observed with slight improvements in the voltammetric peak
potentials using the TiO2–GO/CPE, which is likely due to a
combination of increased surface area and favourable
electrochemical activity largely from the TiO2 and GO. The
electroactive area of each of the electrodes was calculated
(see ESI Fig. S3†). The calculated areas were found to corres-
pond to 0.055, 0.074, 0.095 and 0.144 cm2 for the CPE, TiO2/
CPE, and GO/CPE, and TiO2–GO/CPE, respectively. This con-
firms that the TiO2–GO/CPE exhibits the largest electrode
surface area.
Next, electrochemical impedance spectroscopy (EIS) was
used to study the electrochemical response of the CPE, TiO2/
Fig. 1 Cyclic voltammograms (A) of 1.0 mM BEN and ANT in BRB (pH 2.0) at a scan rate of 0.1 V s−1 utilising a CPE (black line), TiO2/CPE (red line),
GO/CPE (purple line) and TiO2–GO/CPE (green line). Additionally shown (B) are the respective electrochemical impedance spectra in a 5.0 mM K3Fe
(CN)6 (1 : 1) solution with a 0.1 M KCl supporting electrolyte.
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CPE, and GO/CPE, and TiO2–GO/CPE; the results are depicted
in Fig. 1B. In order to obtain detailed data of the impedance
spectroscopy, a simple equivalent circuit model was used to fit
the results. In this circuit, Rs, C and RCT represent solution
resistance, a capacitance for the double-layer and electron
transfer resistance, respectively. By fitting the data, the values
of RCT were estimated to correspond to 4207.0 Ω at the bare
CPE, which decreases to 2509.0 and 1877.0 Ω for the TiO2/CPE
and GO/CPE, respectively, which is then observed to further
decrease to 160.0 Ω for the TiO2–GO/CPE, indicating the sig-
nificantly lower electron-transfer resistance of the TiO2–GO/
CPE compared with other electrodes. The results are consistent
with the CV results presented above, demonstrating that the
TiO2–GO/CPE composite likely provides higher electron con-
duction pathways due to the synergistic eﬀects of its constitu-
ents. Overall, the electrochemical results demonstrate that the
TiO2–GO/CPE provides enhancements over other possible elec-
trode alternatives.
The influence of solution pH upon the electrochemical oxi-
dation of BEN and ANT using the TiO2–GO/CPE was next
explored; pH is an important parameter, which can aﬀect the
electrochemical (analytical) sensitivity and voltammetric peak
separation. Fig. S4† depicts the response upon the electro-
chemical oxidation of BEN and ANT from changing the solu-
tion pH from 2 to 8 which shows that the electrochemical oxi-
dation peak potential for BEN and ANT is pH dependent
as indicated by the following equations: BEN: Ep (V) =
1.17–0.062 pH (R2 = 0.992); ANT: Ep (V) = 1.45–0.052 pH (R
2 =
0.991). Both responses are close to the anticipated Nernstian
value of 59.2 mV for an electrochemical process with equal
electrons and protons. Additionally, ESI Fig. S4† shows the
response of the peak current as a function of pH where it is
observed that pH 2 BRB gives rise to the largest peak currents/
analytical signals for both BEN and ANT.
Furthermore, the eﬀect of the voltammetric scan rate on
the electrochemical signal of BEN and ANT was explored;
these results are presented in ESI Fig. S5,† which demonstrate
that the electrochemical oxidations of both BEN and ANT are
diﬀusion-controlled processes. Additionally, chronoampero-
metric measurements were performed providing information
on the diﬀusion coeﬃcients, which were calculated to be 4.95
× 10−6 cm2 s−1 and 2.34 × 10−6 cm2 s−1, for BEN and ANT,
respectively; further details are provided in the ESI.†
Lastly, the influence of the amount of TiO2 and GO used in
the fabrication of the TiO2–GO/CPE on the magnitude of the
analytical signal/peak current was explored. The anodic peak
currents for both drugs were investigated towards changing
the quantity of TiO2–GO over the range from 5.0 mg to
30.0 mg. The results indicated that the anodic peak current
was optimal when the CPE was modified with a quantity equi-
valent to 30.0 mg of the TiO2–GO nanocomposite (15.0 mg of
TiO2 and 15.0 mg of GO). More quantities of TiO2–GO
increased the background current and poorer repeatability of
the BEN and ANT response was observed.
3.2 Individual and simultaneous voltammetric
determination of BEN and ANT using square wave
voltammetry (SWV)
The electrochemical sensing of BEN and ANT was first
explored at the TiO2–GO/CPE using SWV in pH 2 BRB individu-
ally, as shown in Fig. 2. From the inspection of Fig. 2 it is clear
that the voltammetric response/analytical signal increases with
increasing concentrations of BEN and ANT with the corre-
sponding calibration plots shown as insets in Fig. 2. In the case
of the electrochemical sensing of BEN, a linear response over
the range from 1.0 × 10−6 to 1.0 × 10−4 M was found with the
following linear regression: Ip (µA) = 0.193C (µM) + 0.845; R
2 =
0.9991. The calculated limit of detection (LOD) was found to
correspond to 2.48 × 10−7 M with a limit of quantitation (LOQ)
of 8.26 × 10−7 M. For the sensing of ANT, a linear response was
observed over the range from 1.20 × 10−8 to 8.0 × 10−5 M
Ip (µA) = 0.353C (µM) + 1.930; R
2 = 0.9992. The calculated
Fig. 2 SWVs for BEN and ANT (A & B respectively) utilising the TiO2–GO/CPE in pH 2.0 BRB, with additional calibration plots for the individual
detection of BEN (inset i) and ANT (inset ii). Note: BEN concentrations correspond to: 1.0 × 10−6 to 1.0 × 10−4 M and ANT concentrations correspond
to: 1.20 × 10−8 to 8.0 × 10−5 M.
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values of the LOD and LOQ were found to correspond to
3.00 × 10−9 and 9.99 × 10−9, respectively, with repeatability and
intermediate precisions of 0.81–0.90% and 0.95–1.09%, for BEN
and ANT, respectively. Additionally the stability of the TiO2–GO/
CPE was investigated, where the peak current was not found to
change following storage in air for 30 days. The modified elec-
trode retained 98.80–99.11% of its initial response.
3.3 Simultaneous determination of BEN and ANT
To test the specificity of the TiO2–GO/CPE proposed sensor, its
electroanalytical response was explored towards the sensing of
BEN in the presence of the frequently co-formulated drug ANT.
This was performed by simultaneously changing the concen-
trations of the drugs and recording the SWVs using the
TiO2–GO/CPE. Fig. 3 depicts the voltammetric response of the
TiO2–GO/CPE sensor towards the sensing of BEN in the presence
of ANT. The results demonstrate well-defined anodic peaks at
potentials of +1.01 and +1.22 V (vs. Ag/AgCl), corresponding to
the oxidation of BEN and ANT, respectively, indicating that the
simultaneous determination of these compounds is feasible.
The inset of Fig. 3 shows the plot of the peak current (Ip) as a
function of BEN and ANT concentrations. The calibration plots
(inset) were linearly related to BEN and ANT over the ranges
from 4.0 × 10−6 to 1.0 × 10−4 M and 2.9 × 10−6 to 73.5 × 10−6 M,
respectively. The regression equations were: Ip (μA) =
0.192C (µM) + 0.507, R2 = 0.9978; and Ip (μA) = 0.349C (µM) + 0.684,
R2 = 0.998; for BEN and ANT, respectively. The analytical sensi-
tivities of the TiO2–GO/CPE sensor towards the sensing of BEN
and ANT are found to be 0.193 and 0.353 μA μM−1, respect-
ively. These values are very close to the value obtained in the
absence of an interfering drug (0.192 and 0.349 μA μM−1, see
Fig. 2), indicating that the electrochemical oxidation processes
of these compounds on the surface of the TiO2–GO/CPE are
independent and therefore, simultaneous determination of
their mixtures is possible without significant interference.
3.4 Reproducibility and stability of the TiO2–GO/CPE
The reproducibility and stability of the TiO2–GO/CPE was
examined by measuring the simultaneous electrochemical
signal of 0.1 mM BEN and ANT. The relative standard devi-
ation (RSD) for the peak current of BEN and ANT in six succes-
sive measurements was 1.9% and 2.2%, respectively, Fig. S8A.†
In addition, the fabrication reproducibility was examined by
using three modified sensors prepared independently, using
the same method, and the RSD was 2.5% and 1.8% for BEN
and ANT, respectively, as shown in Fig. S8B.† Also, the inter-
day precision was deduced using diﬀerent drug concentrations
over a period of three days. Intra-day and inter-day precisions
were expressed as the relative standard deviation (RSD%),
Table S1.† For all concentration levels, the RSD didn’t exceed
2.78%, revealing good precision of the TiO2–GO/CPE.
3.5 Analysis of real and spiked plasma samples
The applicability of the TiO2–GO/CPE for the sensing of BEN
in oral fluid (saliva as the real sample), both BEN and ANT in
ear drops (Otosept ear drops (300 mg ANT 100 mg BEN,
spiked samples)) and BEN in Zora-C lozenges; 1 mg per tablet
was explored. The concentrations were measured via the stan-
dard addition method. The results are shown in Table 1. The
recovery values show good accuracy of the proposed TiO2–GO/
CPE sensor. It is very clear that this TiO2–GO/CPE sensor
has potential for the determination of trace amounts of
these compounds in biological fluids and pharmaceutical
products.
Fig. 3 SWVs utilising a TiO2–GO/CPE sensing platform containing
diﬀerent concentrations of BEN and ANT correspond to 4.0 × 10−6 to
1.0 × 10−4 M and 2.9 × 10−6 to 73.5 × 10−6 M, respectively, within a pH
2.0 BRB. Scan rate: 0.1 V s−1. Inset i: calibration plots for the simul-
taneous detection of BEN and ANT.
Table 1 Determination of BEN and ANT in pharmaceutical formulations
and an oral ﬂuid (saliva) sample using the new proposed sensing
protocol
Sample
Amount added
standard (µM)
Amount
found (µM)
Apparent
recoverya %
Oral fluid (saliva) 6.00 5.98 99.67%
BEN 30.00 29.78 99.27%
90.00 89.94 99.93%
Recovery% ± R.S.D 99.62% ± 0.333
Otosept ear drops
(300 mg ANT
100 mg BEN)
4.00 3.99 99.75%
BEN 10.00 10.28 100.28%
25.00 24.91 99.64%
Recovery% ± R.S.D 99.89% ± 0.342
12.00 12.10 100.83%
ANT 30.0 30.27 100.90%
75.00 75.42 100.56%
Recovery% ± R.S.D 100.76% ± 0.179
Zora-C lozenges
(1 mg per tablet)
6.00 5.89 98.20%
BEN 20.00 19.73 98.65%
85.00 84.86 99.84%
Recovery% ± R.S.D 98.89% ± 0.847
a Average of three determinations.
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4. Conclusions
We have reported the simultaneous determination of BEN and
ANT using a TiO2–GO/CPE based electrochemical sensing plat-
form that provides a simple, selective and reliable sensor for
simultaneous determination of TiO2–GO/CPE. We believe this
to be the first example using this sensor towards the electro-
chemical detection of both BEN and ANT. The sensor is found
to exhibit useful analytical ranges in a model matrix and is
applied for the sensing of BEN and ANT in oral fluid (saliva)
and pharmaceutical products. The TiO2–GO/CPE provides a
simple, selective and economical sensor for BEN and ANT and
precludes expensive and time-consuming pre-treatments such
as those used in chromatographic methods.
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